MARKET

CEMI

CEMI

Chembio
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.350
+0.050
+1.52%
Opening 13:03 05/11 EDT
OPEN
3.220
PREV CLOSE
3.300
HIGH
3.395
LOW
3.100
VOLUME
260.88K
TURNOVER
--
52 WEEK HIGH
13.33
52 WEEK LOW
3.010
MARKET CAP
67.82M
P/E (TTM)
-2.5073
1D
5D
1M
3M
1Y
5Y
DJ Chembio Diagnostics' CEO Rick Eberly on Q1 2021 Results -- Earnings Call Transcript >CEMI
Dow Jones · 1d ago
Point of Care Infectious Disease Market Size, Share and Manufacture Development Analysis Report| COVID 19 impact on Top Key Players | Historic, Estimates and Forecast Market Analysis: 2016-2027
May 07, 2021 (The Expresswire) -- The “Point of Care Infectious Disease Market” research report presents bits of knowledge on the current and future industry...
The Express Wire · 4d ago
BRIEF-Chembio Diagnostics Reports First Quarter 2021 Financial Results
reuters.com · 4d ago
8-K: CHEMBIO DIAGNOSTICS, INC.
false001-35569555...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 4d ago
10-Q: CHEMBIO DIAGNOSTICS, INC.
(EDGAR Online via COMTEX) -- ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following discussion and...
Edgar Online - (EDG = 10Q, 10K) · 4d ago
Chembio Diagnostics Q1 EPS $(0.22) Beats $(0.32) Estimate, Sales $8.70M Beat $8.19M Estimate
Chembio Diagnostics (NASDAQ:CEMI) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.32) by 31.25 percent. This is a 12 percent increase over losses of $(0.25) per share from
Benzinga · 4d ago
Chembio Diagnostics EPS beats by $0.10, beats on revenue
Chembio Diagnostics (CEMI): Q1 GAAP EPS of -$0.22 beats by $0.10.Revenue of $8.72M (+27.1% Y/Y) beats by $0.53M.Press Release
Seekingalpha · 4d ago
Chembio Diagnostics, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / May 6, 2021 / Chembio Diagnostics, Inc. (NASDAQ:CEMI) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 6, 2021 at 4:30 PM Eastern Time.
ACCESSWIRE · 4d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CEMI. Analyze the recent business situations of Chembio through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CEMI stock price target is 8.00 with a high estimate of 8.00 and a low estimate of 8.00.
EPS
Institutional Holdings
Institutions: 124
Institutional Holdings: 10.12M
% Owned: 50.00%
Shares Outstanding: 20.24M
TypeInstitutionsShares
Increased
21
380.88K
New
25
2.37M
Decreased
17
556.80K
Sold Out
6
121.68K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.64%
Pharmaceuticals & Medical Research
-0.62%
Key Executives
Chairman/Executive Director
Gail Page
President/Chief Executive Officer/Director
Richard Eberly
Chief Financial Officer/Executive Vice President
Neil Goldman
Executive Vice President/Chief Technology Officer/Chief Scientific Officer
Javan Esfandiari
Vice President/Director of Sales/Director of Marketing
Chuck Caso
Director
David Acheson
Director
David Bespalko
Independent Director
Katherine Davis
Independent Director
Mary Polan
Independent Director
John Potthoff
No Data
About CEMI
Chembio Diagnostics, Inc. is a provider of point-of-care diagnostic products for the detection and diagnosis of infectious diseases. The Company is primarily focused on expanding its product portfolio based upon its Dual Path Platform (DPP). The Company's products include rapid tests for the detection of human immunodeficiency virus (HIV) 1/2 antibodies, and a multiplex rapid test for the detection of HIV and Syphilis antibodies. The Company’s point-of-care infectious disease portfolio is comprised of multiple commercial products and are performed with a tiny drop of blood from the fingertip and provide results in approximately 15 minutes. The Company’s products include DPP HIV 1/2, DPP HIV-Syphilis, DPP Syphilis Screen and Confirm, DPP Zika, DPP Leishmaniasis, STAT-PAK HIV 1/2, STAT-PAK Chagas, SURE CHECK HIV 1/2 and SURE CHECK HIV 1/2 Self- Test.

Webull offers kinds of Chembio Diagnostics Inc stock information, including NASDAQ:CEMI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CEMI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CEMI stock methods without spending real money on the virtual paper trading platform.